Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL ) 3.939 +0.069 (+1.78%) Streaming Delayed Price Updated: 10:48 AM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vigil Neuroscience, Inc. - Common Stock < Previous 1 2 3 4 5 Next > Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 September 17, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Cantor Global Healthcare Conference September 16, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Upcoming September Investor Conferences August 29, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience: Q4 Earnings Insights March 26, 2024 Via Benzinga VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024 August 13, 2024 VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update August 13, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics August 01, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC) July 30, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker July 24, 2024 Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. The data support... Via Benzinga Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease July 24, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference July 18, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP July 18, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today? June 27, 2024 Tonix Pharmaceuticals stock is falling on Thursday after the company announced a proposed public offering for shares of TNXP. Via InvestorPlace Why Is Branchout Food (BOF) Stock Down 39% Today? June 27, 2024 Branchout Food stock is down on Thursday after the company priced an offering of 1.75 million shares of BOF at 80 cents each. Via InvestorPlace Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today? June 27, 2024 Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday June 27, 2024 Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! Via InvestorPlace Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi June 27, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session June 12, 2024 Via Benzinga 3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition June 11, 2024 Penny stocks are risky because of their insane volatility — but these have a chance to 10x your investments. Via InvestorPlace 3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition June 11, 2024 Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. Via InvestorPlace Vigil Neuroscience to Present in Upcoming June Investor Conferences May 30, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Intraday Session May 08, 2024 Via Benzinga Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference May 08, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024 May 07, 2024 VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update May 07, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting April 17, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023 March 26, 2024 VIGL stock results show that Vigil Neuroscience missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 26, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer March 20, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting March 13, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
